WuXi Biologics Statistics

Total Valuation

WuXi Biologics has a market cap or net worth of HKD 109.81 billion. The enterprise value is 107.57 billion.

Market Cap	109.81B
Enterprise Value	107.57B

Important Dates

The last earnings date was Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

WuXi Biologics has 4.10 billion shares outstanding. The number of shares has decreased by -2.80% in one year.

Current Share Class	n/a
Shares Outstanding	4.10B
Shares Change (YoY)	-2.80%
Shares Change (QoQ)	-1.35%
Owned by Insiders (%)	0.36%
Owned by Institutions (%)	35.04%
Float	3.50B

Valuation Ratios

The trailing PE ratio is 32.10 and the forward PE ratio is 22.57. WuXi Biologics's PEG ratio is 1.75.

PE Ratio	32.10
Forward PE	22.57
PS Ratio	5.50
PB Ratio	2.47
P/TBV Ratio	2.59
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	1.75

Financial Ratio History

Enterprise Valuation

EV / Earnings	30.12
EV / Sales	5.41
EV / EBITDA	18.11
EV / EBIT	22.04
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.11.

Current Ratio	2.73
Quick Ratio	1.98
Debt / Equity	0.11
Debt / EBITDA	0.89
Debt / FCF	n/a
Interest Coverage	29.10

Financial Efficiency

Return on equity (ROE) is 8.82% and return on invested capital (ROIC) is 5.79%.

Return on Equity (ROE)	8.82%
Return on Assets (ROA)	5.05%
Return on Invested Capital (ROIC)	5.79%
Return on Capital Employed (ROCE)	9.48%
Revenue Per Employee	1.58M
Profits Per Employee	284,012
Employee Count	12,575
Asset Turnover	0.33
Inventory Turnover	6.71

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +94.77% in the last 52 weeks. The beta is 0.73, so WuXi Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.73
52-Week Price Change	+94.77%
50-Day Moving Average	22.72
200-Day Moving Average	16.24
Relative Strength Index (RSI)	59.63
Average Volume (20 Days)	52,840,151

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, WuXi Biologics had revenue of HKD 19.87 billion and earned 3.57 billion in profits. Earnings per share was 0.83.

Revenue	19.87B
Gross Profit	8.14B
Operating Income	4.88B
Pretax Income	5.14B
Net Income	3.57B
EBITDA	5.94B
EBIT	4.88B
Earnings Per Share (EPS)	0.83

Full Income Statement

Balance Sheet

The company has 11.40 billion in cash and 5.26 billion in debt, giving a net cash position of 6.14 billion or 1.50 per share.

Cash & Cash Equivalents	11.40B
Total Debt	5.26B
Net Cash	6.14B
Net Cash Per Share	1.50
Equity (Book Value)	48.40B
Book Value Per Share	10.84
Working Capital	15.91B

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 40.97%, with operating and profit margins of 24.55% and 17.97%.

Gross Margin	40.97%
Operating Margin	24.55%
Pretax Margin	25.89%
Profit Margin	17.97%
EBITDA Margin	29.88%
EBIT Margin	24.55%
FCF Margin	n/a

Dividends & Yields

WuXi Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.80%
Shareholder Yield	2.80%
Earnings Yield	3.25%
FCF Yield	n/a

Stock Splits

The last stock split was on November 16, 2020. It was a forward split with a ratio of 3.

Last Split Date	Nov 16, 2020
Split Type	Forward
Split Ratio	3

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a